WINTON GROUP Ltd Acquires Shares of 114,182 Henry Schein, Inc. $HSIC

WINTON GROUP Ltd bought a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 114,182 shares of the company’s stock, valued at approximately $7,578,000. WINTON GROUP Ltd owned about 0.10% of Henry Schein at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of HSIC. CYBER HORNET ETFs LLC acquired a new stake in Henry Schein during the 2nd quarter worth $25,000. MUFG Securities EMEA plc purchased a new stake in shares of Henry Schein in the second quarter valued at about $27,000. Sentry Investment Management LLC raised its holdings in shares of Henry Schein by 132.1% in the third quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock valued at $59,000 after buying an additional 515 shares during the last quarter. Evelyn Partners Investment Management Services Ltd acquired a new stake in shares of Henry Schein during the second quarter worth about $62,000. Finally, Mather Group LLC. purchased a new position in shares of Henry Schein during the third quarter worth about $71,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Henry Schein

In other news, EVP Mark E. Mlotek sold 5,925 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total value of $478,740.00. Following the completion of the transaction, the executive vice president owned 80,554 shares in the company, valued at $6,508,763.20. This trade represents a 6.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Philip A. Laskawy sold 2,844 shares of the firm’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $80.36, for a total transaction of $228,543.84. Following the completion of the sale, the director owned 21,961 shares of the company’s stock, valued at $1,764,785.96. This trade represents a 11.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 101,712 shares of company stock valued at $8,251,789. 1.14% of the stock is owned by company insiders.

Henry Schein Stock Performance

NASDAQ HSIC opened at $77.60 on Monday. The company has a current ratio of 1.38, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $78.20 and its two-hundred day moving average is $72.63. Henry Schein, Inc. has a 12-month low of $60.56 and a 12-month high of $89.29. The stock has a market capitalization of $8.90 billion, a price-to-earnings ratio of 23.73, a PEG ratio of 2.30 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The business had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same period last year, the firm earned $1.19 EPS. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on HSIC. Mizuho upped their price objective on Henry Schein from $81.00 to $88.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Leerink Partners lifted their target price on Henry Schein from $75.00 to $87.00 and gave the company a “market perform” rating in a research note on Tuesday, February 24th. UBS Group upped their price target on Henry Schein from $79.00 to $87.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. JPMorgan Chase & Co. increased their price target on Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Finally, Wells Fargo & Company boosted their price objective on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Henry Schein has a consensus rating of “Hold” and a consensus price target of $85.58.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.